Quinoline Derivatives Are Therapeutic Candidates for Transmissible Spongiform Encephalopathies

Journal of Virology

Volumn 78, Issue 3, 2004, Pages 1281-1288

  Murakami Kubo, Ikuko ^a   Doh Ura, Katsumi ^a,c   Ishikawa, Kensuke ^a   Kawatake, Satoshi ^a,c   Sasaki, Kensuke ^a   Kira, Jun Ichi ^a   Ohta, Shigeru ^b   Iwaki, Toru ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

(6 ETHINYL 1 AZABICYCLO[2.2.2]OCT 2 YL)(6 METHOXY 4 QUINOLINYL)METHANONE; 2 QUINOLINYLHYDRAZONE 2 PYRIDINECARBOXALDEHYDE; 4 (4 DIMETHYLAMINOSTYRYL)QUINOLINE; 5 CHLORO 7 IODO 8 QUINOLINEDIOL; 6' METHOXY CINCHONAN 9 OL ACETATE; 6' METHOXY CINCHONAN 9 OL ETHYLCARBONATE; 8 ACETOXYQUINOLINE; 8 HYDROXY 8 QUINOLINYLHYDRAZONE 2 QUINOLINECARBOXALDEHYDE; 8 QUINOLINOL; BIQUINOLINE; CINCHONIDINE; CINCHONINE; HYDROQUINIDINE 4 METHYL 2 QUINOLYL ETHER; HYDROQUINIDINE ANTHRAQUINONE 1,4 DIYL DIETHER; HYDROQUININE; HYDROQUININE ANTHRAQUINONE 1,4 DIYL DIETHER; MEPACRINE; N,N DIMETHYL N' [2 (4 PYRIDINYL) 4 QUINOLINYL] 1,2 ETHANEDIAMINE; PRION PROTEIN; QUINIDINE; QUININE; QUINOLINE; QUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG MECHANISM; DRUG SCREENING; IMMUNOHISTOCHEMISTRY; INCUBATION TIME; MOUSE; NEUROBLASTOMA CELL; NONHUMAN; PRION DISEASE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; SCRAPIE; STRUCTURE ACTIVITY RELATION; SURFACE PLASMON RESONANCE; WESTERN BLOTTING;

ANIMALS; BRAIN; HUMANS; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRAVENTRICULAR; MICE; MICE, TRANSGENIC; NEUROBLASTOMA; PRION DISEASES; PRPSC PROTEINS; QUINACRINE; QUININE; QUINOLINES; STRUCTURE-ACTIVITY RELATIONSHIP; SURFACE PLASMON RESONANCE; TUMOR CELLS, CULTURED;

EID: 0347003596     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.78.3.1281-1288.2004     Document Type: Article

References (19)

1. Barret, A., F. Tagliavini, G. Forloni, C. Bate, M. Salmona, L. Colombo, A. De Luigi, L. Limido, S. Suardi, G. Rossi, F. Auvre, K. T. Adjou, N. Sales, A. Williams, C. Lasmezas, and J. P. Deslys. 2003. Evaluation of quinacrine treatment for prion diseases. J. Virol. 77:8462-8469.
2. Brown, D. R., F. Hafiz, L. L. Glasssmith, B. S. Wong, I. M. Jones, C. Clive, and S. J. Haswell. 2000. Consequences of manganese replacement of copper for prion protein function and proteinase resistance. EMBO J. 19:1180-1186.
3. Brown, D. R., K. Qin, J. W. Herms, A. Madlung, J. Manson, R. Strome, P. E. Fraser, T. Kruck, A. von Bohlen, W. Schulz-Schaeffer, A. Giese, D. Westaway, and H. Kretzschmar. 1997. The cellular prion protein binds copper in vivo. Nature 390:684-687.
4. Brown, P., M. Preece, J. P. Brandel, T. Sato, L. McShane, I. Zerr, A. Fletcher, R. G. Will, M. Pocchiari, N. R. Cashman, J. H. d'Aignaux, L. Cervenakova, J. Fradkin, L. B. Schonberger, and S. J. Collins. 2000. Iatrogenic Creutzfeldt-Jakob disease at the millennium. Neurology 55:1075-1081.
5. Caughey, B., and G. J. Raymond. 1993. Sulfated polyanion inhibition of scrapie-associated PrP accumulation in cultured cells. J. Virol. 67:643-650.
6. Cherny, R. A., C. S. Atwood, M. E. Xilinas, D. N. Gray, W. D. Jones, C. A. McLean, K. J. Barnham, I. Volitakis, F. W. Fraser, Y. Kim, X. Huang, L. E. Goldstein, R. D. Moir, J. T. Lim, K. Beyreuther, H. Zheng, R. E. Tanzi, C. L. Masters, and A. I. Bush. 2001. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30:665-676.
7. Collins, S. J., V. Lewis, M. Brazier, A. F. Hill, A. Fletcher, and C. L. Masters. 2002. Quinacrine does not prolong survival in a murine Creutzfeldt-Jakob disease model. Ann. Neurol. 52:503-506.
8. Doh-ura, K., T. Iwaki, and B. Caughey. 2000. Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation. J. Virol. 74:4894-4897.
9. Doh-ura, K., E. Mekada, K. Ogomori, and T. Iwaki. 2000. Enhanced CD9 expression in the mouse and human brains infected with transmissible spongiform encephalopathies. J. Neuropathol. Exp. Neurol. 59:774-785.
10. Fischer, M., T. Rulicke, A. Raeber, A. Sailer, M. Moser, B. Oesch, S. Brandner, A. Aguzzi, and C. Weissmann. 1996. Prion protein (PrP) with aminoproximal deletions restoring susceptibility of PrP knockout mice to scrapie. EMBO J. 15:1255-1264.
11. Korth, C., B. C. May, F. E. Cohen, and S. B. Prusiner. 2001. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc. Natl. Acad. Sci. USA 98:9836-9841.
12. McKenzie, D., J. Bartz, J. Mirwald, D. Olander, R. Marsh, and J. Aiken. 1998. Reversibility of scrapie inactivation is enhanced by copper. J. Biol. Chem. 273:25545-25547.
13. Miura, T., A. Hori-i, H. Mototani, and H. Takeuchi. 1999. Raman spectroscopic study on the copper(II) binding mode of prion octapeptide and its pH dependence. Biochemistry 38:11560-11569.
14. Priola, S. A., A. Raines, and W. S. Caughey. 2000. Porphyrin and phthalocyanine antiscrapie compounds. Science 287:1503-1506.
15. Prusiner, S. B. 1991. Molecular biology of prion diseases. Science 252:1515-1522.
16. Race, R. E., B. Caughey, K. Graham, D. Ernst, and B. Chesebro. 1988. Analyses of frequency of infection, specific infectivity, and prion protein biosynthesis in scrapie-infected neuroblastoma cell clones. J. Virol. 62:2845-2849.
17. Race, R. E., S. A. Priola, R. A. Bessen, D. Ernst, J. Dockter, G. F. Rall, L. Mucke, B. Chesebro, and M. B. Oldstone. 1995. Neuron-specific expression of a hamster prion protein minigene in transgenic mice induces susceptibility to hamster scrapie agent. Neuron 15:1183-1191.
18. Viles, J. H., F. E. Cohen, S. B. Prusiner, D. B. Goodin, P. E. Wright, and H. J. Dyson. 1999. Copper binding to the prion protein: structural implications of four identical cooperative binding sites. Proc. Natl. Acad. Sci. USA 96:2042-2047.
19. Will, R. G., J. W. Ironside, M. Zeidler, S. N. Cousens, K. Estibeiro, A. Alperovitch, S. Poser, M. Pocchiari, A. Hofman, and P. G. Smith. 1996. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 347:921-925.